CJC-1295 No DAC (also known as Mod GRF 1-29 or Modified GRF) is a 29-amino acid synthetic analog of human Growth Hormone Releasing Hormone (GHRH) — the hypothalamic peptide that signals the pituitary to release growth hormone. Unlike the DAC (Drug Affinity Complex) version, CJC-1295 No DAC retains a short 30-minute half-life that produces physiologically pulsatile GH release when paired with a GHRP like Ipamorelin.

The GHRH Side of the Equation

The GH axis operates through two complementary signals from the hypothalamus: 1. GHRH — stimulates GH secretion ("gas pedal") 2. Somatostatin — inhibits GH secretion ("brake pedal")

GHRPs (like Ipamorelin) work at the pituitary level to amplify GH release in response to existing GHRH signals. CJC-1295 No DAC delivers the GHRH signal itself — independently stimulating the pituitary GHRH-R to initiate GH secretion. When both signals arrive simultaneously, the combined effect on GH pulse amplitude is multiplicative (3–5×), not merely additive.

Why No DAC vs. CJC-1295 With DAC

CJC-1295 No DAC and CJC-1295 With DAC are fundamentally different compounds despite similar names:

| Feature | No DAC | With DAC | |---|---|---| | Half-life | 30 minutes | 8–14 days | | GH release pattern | Pulsatile (natural) | Blunted continuous elevation | | Appropriate pairing | Ipamorelin or GHRP | Can be used alone | | Ideal use case | Natural pulsatile protocols | Convenience/less frequent injection |

The No DAC version is preferred by most advanced researchers because pulsatile GH release more closely mirrors the body's natural secretion pattern — protecting pituitary sensitivity and avoiding the IGF-1 suppression that can occur with constant GH elevation.

Modifications for Stability

CJC-1295 No DAC incorporates four amino acid substitutions vs. native GHRH(1-29): Ala2Ser (position 2), Gln8Ala (position 8), Ser27Leu (position 27), and Leu26 to Norleucine (position 26). These substitutions protect the peptide from rapid degradation by DPP-IV and other serum peptidases — extending its biologically active window from the ~7 minutes of native GHRH to approximately 30 minutes, sufficient for a clean GH pulse while maintaining pulsatile kinetics.

The Ipamorelin + CJC-1295 No DAC Stack: Science Behind the Synergy

This combination has become the most popular GH optimization stack in the research peptide community — and the mechanism is clear. GHRH (CJC-1295 No DAC) and GHRPs (Ipamorelin) work through completely different pituitary receptors: - GHRH-R: Gs-coupled receptor — increases cAMP, activates PKA, triggers GH exocytosis - GHS-R1a: Gq-coupled receptor — activates PKC and intracellular calcium, triggers GH exocytosis

When both pathways are activated simultaneously, the converging intracellular signals produce a GH pulse 3–5× larger than either peptide alone. For a 10mg CJC-1295 No DAC vial at 100–200mcg per injection, users have approximately 50–100 injections worth of supply — sufficient for 10–20 weeks when used daily.